- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI Summary - About
Maze Therapeutics, Inc. Common Stock(MAZE)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Advisory Performance History (Simulated)
Upturn Advisory & Investor View for MAZE
11/13/2026: MAZE (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Maze Therapeutics is a clinical-stage biopharmaceutical company that utilizes its proprietary Compass platform to develop small molecule precision medicines for renal and metabolic diseases. The company's primary operational strengths lie in its human genetics-driven discovery engine and advanced clinical candidates like MZE829. Its core investment narrative centers on unlocking substantial value through upcoming phase II clinical readouts and strategic pharmaceutical collaborations. However, key risks include a pre-commercial revenue profile, clinical trial execution uncertainties, and high capital burn. The stock suits growth-oriented investors with a high-risk tolerance who can monitor ongoing clinical milestones and pipeline updates.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Strong fit | Offers significant upside potential driven by clinical-stage pipeline advancements and genetics-led target discovery. |
| Momentum investor | Strong fit while signal remains positive | Trading patterns react dynamically to clinical trial data readouts and sector-wide biotech momentum signals. |
| Value investor | Weak fit | Lack of current commercial earnings and positive net income makes traditional valuation metrics inapplicable. |
| Dividend investor | Weak fit | The company does not pay dividends and retains all capital for clinical development. |
| Low-risk investor | Weak fit | High clinical trial and regulatory volatility expose investors to significant binary pipeline risks. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | Clinical-stage biotechnology stocks experience sharp price swings based on data readouts and market sentiment. |
| Valuation risk | Medium / high | Valuations rely heavily on future clinical success and projected commercial potential rather than current earnings. |
| Competition risk (rare disease and precision medicine competition) | Medium / high | Well-capitalized peers are aggressively pursuing similar genetic targets in renal and metabolic markets. |
| Business quality | Medium | Backed by a scientifically validated platform, but lacks the commercial maturity of diversified drug manufacturers. |
| Dividend income | Low / none | Income-focused investors receive no dividend yield from common shares. |
| Execution risk | High | Success depends entirely on successfully completing clinical trials and securing regulatory drug approvals. |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.88B USD | Price to earnings Ratio - | 1Y Target Price 62.46 |
Price to earnings Ratio - | 1Y Target Price 62.46 | ||
Volume (30-day avg) 738.7K shares | Beta - | 52 Weeks Range 21.95 - 53.65 | Updated Date 11/15/2026 |
52 Weeks Range 21.95 - 53.65 | Updated Date 11/15/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.62 |
Sector & Industry Intelligence
Sector
Healthcare
Bullish- Sentiment
- Strong Bullish
- Momentum
- Momentum Steady
- BUY participation
- 62.6%
- Active BUY / eligible
- 72 / 115
- 30-Day BUY Count Change
- +35
- Market state
- Strong Bullish
The number of qualifying BUY stocks has remained relatively stable.
Industry
Biotechnology
- BUY participation
- 45.5%
- Active BUY / eligible
- 20 / 44
- 30-Day BUY Count Change
- +13
Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.
Price Behavior

Downtrend
The stock has experienced a sustained decline in price over recent periods.

Extreme Price Shocks
The stock has experienced exceptionally large and disruptive price movements during the period.
Analysis of Past Performance
Type Stock | Historic Profit 44.24% | Avg. Invested days 47 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Advisory Rating ![]() | Upturn Advisory Performance | Stock Returns Performance |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals 
Financial Health Rating 
Growth Momentum Score 
Ownership 
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue) 
Economic Dimensions
Quantitative Style Profile 
Style Classification
Quality Focused
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Collaboration and Licensing Agreements | Upfront payments, research funding, and milestone fees from pharmaceutical partners like Shionogi and Neurocrine. | Revenue currently stems from partnership deals rather than commercial product sales. |
| Future Product Commercialization | Anticipated future sales of small molecule precision medicines once clinical assets like MZE829 are approved. | Long-term value creation depends on successfully commercializing pipeline candidates. |
Valuation
Trailing PE - | Forward PE 8.53 | Enterprise Value 1.55B | Price to Sales(TTM) 93.86 |
Enterprise Value 1.55B | Price to Sales(TTM) 93.86 | ||
Enterprise Value to Revenue 77.39 | Enterprise Value to EBITDA 6.14 | Shares Outstanding 54.68M | Shares Floating 35.97M |
Shares Outstanding 54.68M | Shares Floating 35.97M | ||
Percent Insiders 1.76 | Percent Institutions 111.89 |
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.

